The Therapeutic Goods Administration (TGA), the Australian Department of Health’s regulator of therapeutic products, unveiled Friday a proposal to reclassify the CBD that would allow it to be sold over the counter in non-therapeutic doses. The Administration also opened a public comment period that will end next month.
Currently, CBD preparations are listed in Annex 4 and are authorized for therapeutic purposes as long as 98% of the cannabinoid content of the preparation is CBD. With the proposed changes, CBD would move to Schedule 3, no longer requiring a prescription, and as long as the following conditions apply:
- Cannabidiol is either of plant origin or synthetic under certain conditions
- The maximum recommended daily dose is 60 mg or less.
- The product is presented in packages containing no more than 30 days’ supply.
- Cannabidiol accounts for 98% or more of the total cannabinoid content of the preparation.
- All cannabinoids, other than CBD, must be only those naturally found in cannabis and must comprise 2% or less of the total cannabinoid content of the preparation.
- The product is intended for adults 18 years of age and older.
This proposal comes after the TGA conducted a “safety review” of CBD products. The World Health Organization (WHO) has recommended that CBD products containing no more than 0.2% THC be removed from international drug control. A vote on this WHO recommendation was expected at the March meeting of the UN Commission on Narcotic Drugs, but the vote was postponed until the December meeting.